Management of Extruding Subcutaneous Hormone Pellet
If a testosterone pellet is extruding, remove the pellet immediately to prevent infection, allow the site to heal completely (typically 4–6 weeks), and then consider switching to a non-pellet formulation such as transdermal gel or intramuscular injections rather than re-implanting, given the high risk of recurrent extrusion.
Immediate Management of Active Extrusion
- Remove the extruding pellet as soon as it is identified to minimize the risk of secondary infection at the implantation site 1, 2.
- Clean the extrusion site with povidone-iodine or chlorhexidine solution and apply a sterile dressing 3.
- Prescribe a short course of oral antibiotics (e.g., cephalexin 500 mg four times daily for 7 days or doxycycline 100 mg twice daily for 7 days) if there is any sign of local infection—erythema, warmth, purulent drainage, or tenderness—because infection is present in approximately 60% of cases that subsequently extrude 4.
- Instruct the patient to keep the site clean and dry, avoid submersion in water (baths, swimming) for at least 2 weeks, and monitor for worsening signs of infection 2, 5.
Risk Factors and Recurrence
- Pellet extrusion occurs in approximately 9–12% of procedures with older Organon pellets, but modern Testopel pellets have a lower reported rate of 0.3–3% in men and <1% in women 2, 5, 3.
- Multiple extrusions are 4.6-fold more common than single extrusions (odds ratio 4.6,95% CI 1.6–18.6), indicating that patients who extrude once are at substantially higher risk of repeat extrusion with subsequent implantation 3.
- Infection is strongly associated with extrusion: among men who develop infection requiring antibiotics, 60% subsequently experience pellet extrusion 4.
- Operator technique influences extrusion risk, with one study identifying a specific operator who had significantly higher rates of both total extrusions (P=0.0002) and infection-related extrusions (P=0.0008) compared to colleagues, though this was not explained by experience or procedural style 3.
- Povidone-iodine skin preparation is associated with fewer extrusions than mixed alcohol solutions 3.
Decision Algorithm: Re-implantation vs. Alternative Formulation
When Re-implantation May Be Considered
- If this is the first extrusion and the patient strongly prefers pellet therapy over other modalities, re-implantation may be attempted after complete healing (4–6 weeks) 2, 5.
- Ensure meticulous adherence to post-procedure instructions: no strenuous activity for 48–72 hours, no submersion in water for 2 weeks, and strict avoidance of direct pressure on the implant site 2.
- Use povidone-iodine (not alcohol-based) skin preparation 3.
- Consider a different anatomical site (e.g., if the initial site was the buttock, use the lateral hip or lower abdomen) 3.
When to Switch to Alternative Formulation
- If this is a second or subsequent extrusion, the 4.6-fold increased risk of multiple extrusions makes continued pellet therapy inadvisable 3.
- If infection was present at the time of extrusion, the 60% subsequent extrusion rate argues strongly against re-implantation 4.
- If the patient is unwilling or unable to comply with post-procedure activity restrictions, pellet therapy is not appropriate 2.
Alternative Testosterone Formulations
First-Line Alternative: Transdermal Gel
- Transdermal testosterone gel 1.62% at 40.5 mg daily provides stable day-to-day testosterone levels, avoids the surgical procedure and extrusion risk of pellets, and has a significantly lower erythrocytosis risk (≈15%) compared to injectable testosterone (≈44%) 6, 7.
- The gel is applied once daily to the shoulders, upper arms, or abdomen; patients must wash hands immediately after application and cover the site with clothing to prevent transfer to partners or children 6.
- Testosterone levels should be measured 2–3 months after initiation, targeting mid-normal values of 450–600 ng/dL 6.
Second-Line Alternative: Intramuscular Injections
- Testosterone cypionate or enanthate 100–200 mg intramuscularly every 2 weeks (or 50–100 mg weekly for more stable levels) is a cost-effective option with an annual cost of approximately $156 compared to $2,135 for transdermal gel 6, 8.
- Weekly dosing (50–100 mg) reduces the "roller-coaster" effect of testosterone peaks and troughs seen with biweekly administration, thereby lowering the risk of erythrocytosis and mood fluctuations 6, 7.
- Testosterone levels should be measured midway between injections (days 5–7 for weekly dosing, days 7–10 for biweekly dosing), targeting 500–600 ng/dL 6, 8.
- Subcutaneous administration of testosterone cypionate/enanthate at the same doses is an increasingly preferred alternative to intramuscular injection, offering comparable efficacy with less discomfort and easier self-administration 6, 7.
Monitoring After Formulation Switch
- Measure total testosterone 2–3 months after switching to the new formulation, then every 6–12 months once stable levels are achieved 6, 8.
- Monitor hematocrit at each visit; withhold therapy if hematocrit exceeds 54% and consider therapeutic phlebotomy in high-risk patients 6, 8.
- In men over 40 years, monitor PSA levels and perform digital rectal examination; refer to urology if PSA rises >1.0 ng/mL within the first 6 months or >0.4 ng/mL per year thereafter 6, 8.
- Assess symptomatic response, particularly sexual function and libido, at each visit; discontinue therapy at 12 months if there is no improvement in sexual symptoms 6, 8.
Common Pitfalls to Avoid
- Do not attempt re-implantation before the extrusion site has completely healed (minimum 4–6 weeks), as premature re-implantation increases infection risk 2, 5.
- Do not re-implant in a patient who has already experienced multiple extrusions, given the 4.6-fold increased risk of recurrence 3.
- Do not ignore signs of infection (erythema, warmth, purulent drainage) at the extrusion site, as untreated infection leads to extrusion in 60% of cases 4.
- Do not use alcohol-based skin preparation for future implantation procedures; povidone-iodine is associated with lower extrusion rates 3.
- Do not assume that washing or antibiotic-soaking pellets prior to implantation will reduce extrusion risk, as randomized trials have shown no benefit from these interventions 3, 4.